Compare Ferrari NV (RACE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Sanofi SA — how do they compare? Ferrari NV trades at $405.75 (market cap $71.13B), while Sanofi SA trades at $43.14 (market cap $104.06B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| RACE | SNY | |
|---|---|---|
Market Cap | $71.13B | $104.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $504.09 | $52.34 |
52-Week Low | $314.63 | $41.33 |
Enterprise Value | $73.08B | $124.09B |
Dividend Yield | 1.04% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, with technical indicators showing a bearish trend while fundamentals remain strong. The company reported solid Q2 2026 earnings of $2.99 EPS, beating estimates, and maintains robust profitability with 22.25% net margins. Recent news highlights Ferrari's first electric vehicle selling for $40 million at auction, demonstrating brand strength. Analyst consensus remains bullish with a $462.67 price target representing 14% upside potential from current levels.
Ferrari presents a compelling growth story with premium valuation justified by strong fundamentals, though elevated multiples leave little room for execution missteps. Key risks include luxury market cyclicality and electric vehicle transition challenges, while institutional buying activity supports long-term confidence. The stock's current technical weakness may present entry opportunities for investors believing in the company's brand power and margin stability.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
